McAdam LLC’s Boston Scientific BSX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$288K Buy
6,601
+1,283
+24% +$59.4K 0.01% 407
2026
Q2
$227K Buy
+5,318
New +$289K 0.01% 452
2026
Q1
– Sell
-2,889
Closed -$275K – 452
2025
Q4
$275K Sell
2,889
-78
-3% -$7.65K 0.01% 339
2025
Q3
$290K Buy
2,967
+563
+23% +$58.3K 0.01% 311
2025
Q2
$258K Buy
2,404
+123
+5% +$12.4K 0.01% 321
2025
Q1
$230K Sell
2,281
-1,435
-39% -$144K 0.01% 303
2024
Q4
$332K Buy
3,716
+199
+6% +$17.5K 0.02% 262
2024
Q3
$295K Buy
+3,517
New +$277K 0.02% 259
2022
Q4
– Sell
-5,966
Closed -$231K – 196
2022
Q3
$231K Sell
5,966
-134
-2% -$5.38K 0.03% 199
2022
Q2
$227K Buy
+6,100
New +$248K 0.02% 201
2018
Q4
– Sell
-105
Closed -$4K – 130
2018
Q3
$4K Hold
105
– – ﹤0.01% 432
2018
Q2
$3K Buy
+105
New +$3.17K ﹤0.01% 447

Other funds holding BSX

McAdam LLC's BSX Position: Q3 2026 in Review

McAdam LLC increased its Boston Scientific (BSX) stake by 24% in Q3 2026, buying an estimated $59.4K and bringing the position to 6,601 shares worth $288K. The position accounts for 0.01% of the portfolio, ranked #407.

McAdam LLC first reported a position in BSX in Q2 2018 and has held it in 12 quarters since. The position peaked at $332K in Q4 2024. 406 funds tracked by Wall St. Rank hold BSX as of Q3 2026.

  • McAdam LLC held 6,601 shares of Boston Scientific worth $288K as of Q3 2026.
  • McAdam LLC bought 1,283 Boston Scientific shares in Q3 2026, an estimated $59.4K.
  • Boston Scientific made up 0.01% of McAdam LLC's portfolio in Q3 2026, its #407 holding.
  • McAdam LLC first reported a position in Boston Scientific in Q2 2018 and has held it in 12 quarters since.
  • McAdam LLC's Boston Scientific position peaked at $332K in Q4 2024.
  • 406 funds tracked by Wall St. Rank held Boston Scientific as of Q3 2026.

Based on McAdam LLC's 13F filing for Q3 2026, filed 21 Oct 2026.